시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 경구 고형제 위탁생산 시장 보고서(2025년)
Oral Solid Dosage Contract Manufacturing Global Market Report 2025
상품코드 : 1825847
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

경구 고형제 위탁생산 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.1%로 558억 1,000만 달러로 성장할 것입니다. 예측 기간의 성장은 제약기업의 아웃소싱 증가, 약물전달 기술의 발전, 의약품 개발 활동의 활성화 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 약물전달 기술의 발전, 3D 프린팅의 통합, 방출 제어 기술의 발전 등을 들 수 있습니다.

향후 5년간 7.1%의 성장률 전망은 지난번 예측보다 0.4% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과로 인해 스위스 및 인도에서 수입되는 연속 제조 장비 및 장용성 코팅제의 비용이 상승하고, 제네릭 의약품의 가격 상승 및 필수 의약품의 공급망 취약성으로 이어져 미국 내 의약품 제조에 차질을 빚을 수 있습니다. 또한, 상호 관세와 무역 마찰 및 제한 강화로 인한 세계 경제 및 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

제네릭 의약품에 대한 수요가 급증하면서 향후 몇 년간 경구 고형제 위탁생산 시장의 성장을 견인할 것으로 예상됩니다. 제네릭 의약품은 용량, 강도, 안전성, 성능, 품질, 사용 목적 등에서 오리지널 의약품과 생물학적으로 동등한 의약품입니다. 제네릭 의약품에 대한 수요 증가는 특허 만료, 비용 절감 노력, 규제적 인센티브, 의료 접근성 확대 노력 등의 요인에 의해 촉진되고 있습니다. 경구 고형제 수탁 제조는 업무 효율성 향상, 비용 절감, 고품질 생산, 시장 출시 가속화 등 수탁 제조사의 역량을 활용하여 제네릭 의약품의 생산과 유통을 촉진하는 데 매우 중요한 역할을 하고 있습니다. 예를 들어, 2022년 미국 식품의약국(FDA)은 미국 내 처방전의 91%가 제네릭 의약품으로 채워질 것이며, FDA가 승인한 제네릭 의약품은 3만 2,000개 이상에 달할 것으로 추산하고 있습니다. 그 결과, 제네릭 의약품에 대한 수요가 경구 고형제 위탁생산 시장의 성장을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Oral solid dosage contract manufacturing involves outsourcing the production of oral solid dosage forms of pharmaceuticals to third-party manufacturers. This strategy enables pharmaceutical companies to concentrate on their core activities, such as research, development, and marketing, while utilizing the expertise and capabilities of contract manufacturing organizations (CMOs) to efficiently produce high-quality oral solid dosage pharmaceuticals.

The main product types in oral solid dosage contract manufacturing include tablets, capsules, powders, granules, and other forms. Tablets are small, solid masses of medicine containing an active drug and excipients. The services offered encompass drug product development, fill-finish product manufacturing, API manufacturing, packaging and labeling, and other applications. The therapeutic areas covered include oncology, cardiovascular diseases, metabolic disorders, neurological disorders, infectious diseases, gastrointestinal diseases, and other therapeutic areas. The end users of these services are large companies, as well as medium and small companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The oral solid dosage contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides oral solid dosage contract manufacturing market statistics, including oral solid dosage contract manufacturing industry global market size, regional shares, competitors with a oral solid dosage contract manufacturing market share, detailed oral solid dosage contract manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the oral solid dosage contract manufacturing industry. This oral solid dosage contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral solid dosage contract manufacturing market size has grown strongly in recent years. It will grow from $39.39 billion in 2024 to $42.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to the growing global population, prevalence of chronic diseases, and rise in focus on research and development.

The oral solid dosage contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $55.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing outsourcing by pharmaceutical companies, advancements in drug delivery technology, and increasing drug development activities. Major trends in the forecast period include advancements in drug delivery technology, integration of 3D printing, and advancements in controlled-release technologies.

The forecast of 7.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. drug production by increasing costs for continuous manufacturing equipment and enteric coating materials imported from Switzerland and India, potentially leading to higher generic drug prices and supply chain vulnerabilities for essential medications. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The surge in demand for generic drugs is anticipated to drive the growth of the oral solid dosage contract manufacturing market in the coming years. Generic drugs are medications that are bioequivalent to brand-name drugs in dosage, strength, safety, performance, quality, and intended use. The increasing demand for generic drugs is fueled by factors such as patent expirations, cost containment initiatives, regulatory incentives, and efforts to expand access to healthcare. Oral solid dosage contract manufacturing plays a pivotal role in facilitating the production and distribution of generic drugs by leveraging the capabilities of contract manufacturers to enhance operational efficiency, reduce costs, ensure high-quality production, and expedite the introduction of products to the market. For example, in 2022, the Food and Drug Administration (FDA) estimated that 91% of all prescriptions in the USA were filled with generic drugs, with over 32,000 generic drugs approved by the FDA. Consequently, the demand for generic drugs propels the growth of the oral solid dosage contract manufacturing market.

Key players in the oral solid dosage contract manufacturing market are concentrating on developing innovative solutions, such as continuous manufacturing lines, to fortify their position in the market. A continuous manufacturing line refers to a production facility or system that employs continuous manufacturing processes to produce pharmaceuticals or other products. For instance, in January 2023, WuXi STA, a pharmaceutical company based in China, inaugurated its first continuous manufacturing line for oral solid pharmaceutical products. This state-of-the-art facility represents a significant advancement in pharmaceutical production, harnessing continuous manufacturing principles to enhance efficiency, quality, and flexibility in drug manufacturing processes. This enhanced agility streamlines production timelines and minimizes downtime, ultimately expediting the delivery of essential medications to patients.

In August 2022, Catalent Inc., a US-based pharmaceutical company, completed the acquisition of Metrics Contract Services for $475 million. Through this acquisition, Catalent seeks to broaden its capabilities in the development and manufacturing of oral solid dosage forms. Metrics Contract Services is a US-based full-service contract development and manufacturing organization (CDMO) specializing in oral dosage forms.

Major companies operating in the oral solid dosage contract manufacturing market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Siemens Healthineers AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under the CordenPharma brand, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation

Asia Pacific was the largest region in the oral solid dosage contract manufacturing market in 2024. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral solid dosage contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as formulation development, analytical and stability testing, and quality assurance and control. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral solid dosage contract manufacturing market also consists of sales of orally disintegrating tablets (ODTS), lozenges, and chewing gums. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Solid Dosage Contract Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral solid dosage contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for oral solid dosage contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral solid dosage contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Oral Solid Dosage Contract Manufacturing Market Characteristics

3. Oral Solid Dosage Contract Manufacturing Market Trends And Strategies

4. Oral Solid Dosage Contract Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Oral Solid Dosage Contract Manufacturing Growth Analysis And Strategic Analysis Framework

6. Oral Solid Dosage Contract Manufacturing Market Segmentation

7. Oral Solid Dosage Contract Manufacturing Market Regional And Country Analysis

8. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market

9. China Oral Solid Dosage Contract Manufacturing Market

10. India Oral Solid Dosage Contract Manufacturing Market

11. Japan Oral Solid Dosage Contract Manufacturing Market

12. Australia Oral Solid Dosage Contract Manufacturing Market

13. Indonesia Oral Solid Dosage Contract Manufacturing Market

14. South Korea Oral Solid Dosage Contract Manufacturing Market

15. Western Europe Oral Solid Dosage Contract Manufacturing Market

16. UK Oral Solid Dosage Contract Manufacturing Market

17. Germany Oral Solid Dosage Contract Manufacturing Market

18. France Oral Solid Dosage Contract Manufacturing Market

19. Italy Oral Solid Dosage Contract Manufacturing Market

20. Spain Oral Solid Dosage Contract Manufacturing Market

21. Eastern Europe Oral Solid Dosage Contract Manufacturing Market

22. Russia Oral Solid Dosage Contract Manufacturing Market

23. North America Oral Solid Dosage Contract Manufacturing Market

24. USA Oral Solid Dosage Contract Manufacturing Market

25. Canada Oral Solid Dosage Contract Manufacturing Market

26. South America Oral Solid Dosage Contract Manufacturing Market

27. Brazil Oral Solid Dosage Contract Manufacturing Market

28. Middle East Oral Solid Dosage Contract Manufacturing Market

29. Africa Oral Solid Dosage Contract Manufacturing Market

30. Oral Solid Dosage Contract Manufacturing Market Competitive Landscape And Company Profiles

31. Oral Solid Dosage Contract Manufacturing Market Other Major And Innovative Companies

32. Global Oral Solid Dosage Contract Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Solid Dosage Contract Manufacturing Market

34. Recent Developments In The Oral Solid Dosage Contract Manufacturing Market

35. Oral Solid Dosage Contract Manufacturing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기